Apolipoprotein A-I (apoAI) amyloidosis is a non-AL, non-AA, and non-transthyretin type of amyloidosis associated with mutations in the APOA1 gene inherited in an autosomal dominant fashion. It is a form of systemic amyloidosis, but at presentation, can also mimic localized amyloidosis. The renal presentation generally involves interstitial and medullary deposition of apo A-I amyloid protein. We describe the identification of apo A-I amyloidosis by mass spectrometry in a 52-year old male, with no family history of amyloidosis, presenting with nephrotic syndrome and associated with heterozygosity for a novel APOA1 mutation (c.220T>A) which encodes the known amyloidogenic Trp50Arg variant. Renal amyloid deposits in this case were confined to the glomeruli alone, and the patient developed progressive renal impairment. One year after diagnosis, the patient had a successful kidney transplant from an unrelated donor. Pathogenic mutation in the APOA1 gene are generally associated with symptoms of amyloidosis. In this family however, genotyping of family members identified several unaffected carriers suggesting a variable disease penetrance, which has not been described before in this form of amyloidosis and has implications when counselling those with APOA1 mutations.
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Introduction:
Amyloidosis is characterized by extracellular deposition of insoluble protein and peptides. Accumulation of amyloid in tissues, as well as oligomers of amyloid protein may cause organ damage, and if affecting the kidney, is often associated with progression to end stage renal disease. [Bergesio F, et al. 2008] Hereditary amyloidosis is caused by mutations in specific, protein encoding genes leading to misfolding and aggregation of the protein. Several proteins have been identified including fibrinogen A-α chain [Benson MD, 2003] , transthyretin [Ando Y, et al. 2013] , apolipoprotein A-I (apo A-I) [Obici L, et al. 2006] , apolipoprotein A-II (apo-AII) [Yazaki M, et al, 2001 ], lysosome [DR Booth et. al 1969] and gelsolin. [Benson MD, 2003] there is a prior family history of similar disease (Table I ) and so far, unaffected mutation carriers have not been described. [Erikson M et al, 2000] Results:
A 
Discussion:
ApoAI amyloidosis in this case was suggested by immuhistochemistry and confirmed by mass spectrometry [Sethi S. et al. 2013 ] and genetic analysis. An extensive work up showed no signs of monoclonal disease or inflammatory disease, supporting the pathogenicity of the glomerular apoAI amyloid deposits presenting with nephrotic syndrome and leading to end stage renal failure.
In general, renal involvement in apoA1 amyloidosis is believed to be medullary/interstitial rather than glomerular. In this case, however, the amyloid deposits were identified only in the glomeruli reported only in three other cases. (Table I) A single case of an identical amino acid substitution due to a different, single nucleotide exchange (APOA1 c.220T>C) has previously been reported in a patient with a family history of amyloidosis. [Booth DR, et al. 1995] . The patient presented with symptoms of amyloidosis at age 35 years and had widespread organ involvement, including liver, spleen, and gastrointestinal tract. Renal involvement was noted in a kidney biopsy; however, kidney function only slowly declined leading to a kidney transplantation 10 years after presentation. In the current case, a culprit APOA1 mutation was identified in several family members with no signs or symptoms of amyloidosis, including the patient's mother at 80-years of age. Thus, the mutation and resulting amino acid substitution is associated with interfamilial and intrafamilial variability in disease penetrance. It is not known whether this may be due to variable expression of the variant. The recognition of this variation in disease penetrance is important for the counselling of clinically unaffected family members with a similar genotype. In conclusion, the current case demonstrates the successful identification of apoAI amyloidosis by proteomic analysis of amyloid deposits associated with a novel APOA1 mutation encoding a previously reported pathogenic apoAI variant. Genotyping of family members identified several unaffected older carriers indicating variable penetrance. The patient presented with nephrotic syndrome, which is unusual in this form of amyloidosis, and the renal biopsy showed isolated glomerular amyloid deposits that may mimic other types of amyloidosis.
